Category: Oncology

Hepatotoxicity and Ceritinib (1) 1. Incidence and Severity: • Common Occurrence: Hepatotoxicity is a recognized adverse effect of ceritinib. Clinical trials have reported elevations in liver enzymes (ALT, AST, and bilirubin) in a significant number of patients.

Ceritinib (Resistance) Resistance • Acquired Resistance: Over time, patients may develop resistance to ceritinib, often due to secondary mutations in the ALK gene or activation of alternative signaling pathways. Research is ongoing to develop new therapies to overcome this resistance

Ceritinib (Side Effects) Gastrointestinal Issues: Diarrhea, nausea, vomiting, and abdominal pain are common side effects. Hepatotoxicity: Elevated liver enzymes and hepatotoxicity can occur, necessitating regular liver function monitoring. Hyperglycemia: Elevated blood sugar levels may occur and should be monitored. Pneumonitis: Interstitial lung disease and pneumonitis are serious but less common side effects. Fatigue and Decreased […]

Ceritinib (Dosage) Dosage: The recommended dose of ceritinib is 450 mg orally once daily with food. The dosage may be adjusted based on individual tolerance and side effects

Ceritinib (Efficacy and Clinical Trials) Clinical Trials Studies have shown that ceritinib can significantly improve progression-free survival (PFS) in patients with ALK-positive NSCLC. It has demonstrated activity in patients who have progressed on crizotinib as well as in crizotinib-naïve patients​. In the ASCEND-4 trial, ceritinib showed superior efficacy compared to chemotherapy in the first-line treatment […]

Ceritinib (Indications) Non-Small Cell Lung Cancer (NSCLC): Ceritinib is approved for the treatment of patients with ALK-positive metastatic NSCLC. It is particularly used in patients who have developed resistance to or cannot tolerate crizotinib, another ALK inhibitor​.